Scorpion Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Scorpion Therapeutics, Inc.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
The oncology start-up signed a co-development and commercialization agreement with the French pharmaceutical company for two next-generation EGFR inhibitors.
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
2021 was an unusual but exciting year for dealmaking in the biopharma industry. How will 2022 compare?
- Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.